Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs
VANCOUVER, British Columbia and SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a transaction with Van Herk Investments, a leading European life science investor, to create and fund a new company called Sairopa, with a pipeline focused on research and development of non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform. Chinook will own approximately 40 percent of Sairopa after the first tranche of financing from Van Herk and have one seat on Sairopa’s Board of Directors.
New Website for People Impacted by Age-Related Macular Degeneration Launched by Patient Advocacy Groups prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
In Short
The Situation: The U.S. Department of Justice ( DOJ ) published its annual report regarding False Claims Act ( FCA ) recoveries for fiscal year 2020 (ending September 2020) and announced its priorities for 2021.
The Result: DOJ s 2020 FCA recoveries totaled more than $2.2 billion, a lower sum than in prior years. Despite the lower overall recoveries, health care fraud still represents the lion s share of FCA recoveries, encompassing cases relating to pharmaceuticals, providers, electronic health records ( EHR ), and opioids. COVID-related cases did not figure significantly in the 2020 FCA results. Nonetheless, FCA filings in 2020 were up substantially despite the global pandemic, closed courts, and the difficulties of remote work, with most of that increase coming from government-initiated cases.
On 25 February 2021 Chief Judge Stark of the US District Court for the District of Delaware ruled in favour of Novartis Pharmaceuticals Corporation against the generic defendants Torrent Pharma Inc and Torrent Pharmaceuticals Ltd in
In re: Entresto (Sacubitril/Valsartan) Patent Litigation (MDL No 20-2930-LPS (D Del)). At the conclusion of oral arguments, Stark ruled in Novartis s favour, denying Torrent s motion for judgment on the pleadings of non-infringement of US Patents 8,877,938 and 9,388,134. These patents cover Novartis s Entresto product and its approved use.
Agreeing with Novartis, Stark found that Torrent had not met its burden of clearly proving that no material issue of fact remained to be resolved and that Torrent was entitled to judgment as a matter of law. Rather, Stark found that Novartis had presented plausible theories for infringement and should be permitted to present additional evidence in support of those theories. Stark further found that Novartis had prese
Novartis Pharma AG: Novartis announces change to the Executive Committee
Thomas Kendris appointed Chief Legal Officer ad interim
Basel, March 5, 2021 - Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021.
Thomas N. Kendris, currently Global Head Litigation and US Country President, will be appointed Chief Legal Officer ad interim and attendee to the ECN in this capacity. Novartis has started an executive search process to evaluate internal and external candidates for the role of its Chief Legal Officer.